PRACA PRZEGLĄDOWA
Włóknienie zaotrzewnowe- aktualny stan wiedzy
Więcej
Ukryj
Data nadesłania: 20-09-2016
Data ostatniej rewizji: 06-10-2016
Data akceptacji: 13-10-2016
Data publikacji online: 28-11-2016
Data publikacji: 28-10-2016
Reumatologia 2016;54(5):256-263
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Retroperitoneal fibrosis (RPF) is a rare disease, hallmarked by inflammation and deposition of fibrous tissue around the abdominal aorta. This process may spread contiguously and involve adjacent structures, leading to many complications, among which the most frequent and most severe is ureteral obstruction. The condition usually has idiopathic origin (idiopathic retroperitoneal fibrosis – IRF), but can also develop secondarily to a number of factors. The etiology of the disease remains unclear. Current research suggests that about half of the cases of IRF may be a symptom of a recently discovered, clinically heterogeneous immunoglobulin G4-related disease (IgG4-RD). Corticosteroids are the first-line treatment for IRF, but effective attempts to use immunosuppressants are also made. This paper presents the current state of knowledge on the etiopathogenesis, clinical presentation, diagnosis and therapeutic possibilities in different forms of RPF. Based on the latest research, an analysis of the relationship between IRF and IgG4-RD was performed.
REFERENCJE (62)
1.
Brandt AS, Kamper L, Kukuk S, et al. Associated findings and complications of retroperitoneal fibrosis in 204 patients: Results of a urological registry. J Urol 2011; 185: 526-531.
2.
Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond’s disease. Medicine (Baltimore) 2013; 92: 82-91.
3.
Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 2009; 33: 1833-1839.
4.
Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 1948; 59: 1072-1079.
5.
Uibu T, Oksa P, Auvinen A, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 2004; 363: 1422-1426.
6.
van Bommel EFH, Jansen I, Hendriksz TR, Aarnoudse ALHJ. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 2009; 88: 193-201.
7.
Miller OF, Smith LJ, Ferrara EX, et al. Presentation of idiopathic retroperitoneal fibrosis in the pediatric population. J Pediatr Surg 2003; 38: 1685-1688.
8.
Parums DV. The spectrum of chronic periaortitis. Histopathology 1990; 16: 423-431.
9.
Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990; 114: 383-387.
10.
Parums DV, Chadwick DR, Mitchinson MJ. The localisation of immunoglobulin in chronic periaortitis. Atherosclerosis 1986; 61: 117-123.
11.
Vaglio A, Manenti L, Allegri L, et al. ANCA-positive periaortic vasculitis: Does it fall within the spectrum of vasculitis? J Intern Med 2002; 251: 268-271.
12.
Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc 2011; 86: 297-303.
13.
Martorana D, Vaglio A, Greco P, et al. Chronic periaortitis and HLA-DRB1*03: Another clue to an autoimmune origin. Arthritis Care Res 2006; 55: 126-130.
14.
Palmisano A, Urban ML, Corradi D, et al. Chronic periaortitis with thoracic aorta and epiaortic artery involvement: A systemic large vessel vasculitis? Rheumatol (United Kingdom) 2015; 54: 2004-2009.
15.
Salvarani C, Pipitone N, Versari A, et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 2005; 53: 298-303.
16.
Vaglio A, Pipitone N, Salvarani C. Chronic periaortitis: a large-vessel vasculitis? Curr Opin Rheumatol 2011; 23: 1-6.
17.
Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet (London, England) 2006; 367: 241-251.
18.
Goldoni M, Bonini S, Urban ML, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: A case-control study. Ann Intern Med 2014; 161: 181-188.
19.
Alberti C. Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology. G Chir 2015; 36: 187-191.
20.
Pfitzenmeyer P, Foucher P, Dennewald G, et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J 1996; 9: 1013-1019.
21.
Couderc M, Mathieu S, Dubost JJ, Soubrier M. Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis. J Rheumatol 2013; 40: 1931-1933.
22.
Amis ES. Retroperitoneal fibrosis. AJR Am J Roentgenol 1991; 157: 321-329.
23.
Corradi D, Maestri R, Palmisano A, et al. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int 2007; 72: 742-753.
24.
Surcel C, Mirvald C, Pavelescu C, et al. Management of idiopathic retroperitoneal fibrosis from the urologist’s perspective. Ther Adv Urol 2015; 7: 85–99.
25.
Vivas I, Nicolás AI, Velázquez P, et al. Retroperitoneal fibrosis: Typical and atypical manifestations. Br J Radiol 2000; 73: 214-222.
26.
Diamond EL, Dagna L, Hyman DM, et al. Review Article Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014; 124: 483-493.
27.
Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25: 1181-1192.
28.
Ebbo M, Daniel L, Pavic M, et al. IgG4-Related systemic disease. Medicine (Baltimore) 2012; 91: 49-56.
29.
Lin W, Lu S, Chen H, et al. Clinical characteristics of immunoglobulin G4-related disease: A prospective study of 118 Chinese patients. Rheumatol (United Kingdom) 2015; 54: 1982-1990.
30.
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22: 21-30.
31.
Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet 2015; 385: 1460-1471.
32.
Koo BS, Koh YW, Hong S, et al. Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Mod Rheumatol 2014; 7595: 1-5.
33.
Castelein T, Coudyzer W, Blockmans D. IgG4-related periaortitis vs idiopathic periaortitis: is there a role for atherosclerotic plaque in the pathogenesis of IgG4-related periaortitis? Rheumatology (Oxford) 2015; 54: 1250-1256.
34.
Stone JH, Zen Y, Deshpande V. IgG4-Related Disease. N Engl J Med 2012; 366: 539-551.
35.
Fujimori N, Ito T, Igarashi H, et al. Retroperitoneal fibrosis associated with immunoglobulin G4-related disease. World J Gastroenterol 2013; 19: 35-41.
36.
Ngwa TN, Law R, Murray D, Chari ST. Serum immunoglobulin G4 level is a poor predictor of immunoglobulin G4-related disease. Pancreas 2014; 43: 704-707.
37.
Palmisano A, Vaglio A. Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res Clin Rheumatol 2009; 23: 339-353.
38.
Warnatz K. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005; 64: 828-833.
39.
Pelkmans LG, Aarnoudse AJ, Hendriksz TR, van Bommel EFH. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant 2012; 27: 2819-2825.
40.
van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse ALHJ. Idiopathic retroperitoneal fibrosis. Medicine (Baltimore) 2009; 88: 193-201.
41.
Li KP, Zhu J, Zhang JL, Huang F. Idiopathic retroperitoneal fibrosis (RPF): Clinical features of 61 cases and literature review. Clin Rheumatol 2011; 30: 601-605.
42.
Cronin CG, Lohan DG, Blake MA, et al. Retroperitoneal fibrosis: A review of clinical features and imaging findings. Am J Roentgenol 2008; 191: 423-431.
43.
Caiafa RO, Vinuesa AS, Izquierdo RS, et al. Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. Radiographics 2013; 33: 535-552.
44.
Gao L, Wang H, Xu Y, Zhang Z. Computed tomography parameters can be used as predictive markers for the improvement of renal function in patients with retroperitoneal fibrosis. Clin Exp Rheumatol 2015; 33: 871-876.
45.
Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157.
46.
Thomsen HS, Morcos SK, Almén T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: Updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013; 23: 307-318.
47.
Nakajo M, Jinnouchi S, Tanabe H, et al. 18F-fluorodeoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis. J Comput Assist Tomogr 2007; 31: 539-543.
48.
Piccoli GB, Consiglio V, Arena V, et al. Positron emission tomography as a tool for the ‘tailored’ management of retroperitoneal fibrosis: a nephro-urological experience. Nephrol Dial Transplant 2010; 25: 2603-2610.
49.
Vaglio A, Greco P, Versari A, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: Active residual disease or silent ‘scar’? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol 2005; 23: 231-234.
50.
van Bommel EFH, Siemes C, Hak LE, et al. Long-Term Renal and Patient Outcome in Idiopathic Retroperitoneal Fibrosis Treated With Prednisone. Am J Kidney Dis 2007; 49: 615-625.
51.
Fry AC, Singh S, Gunda SS, et al. Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: A retrospective study. Nephron - Clin Pract 2008; 108: 213-220.
52.
Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011; 378: 338-346.
53.
Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 2013; 72: 1584-1586.
54.
Scavalli AS, Spadaro A, Riccieri V, et al. Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. Clin Rheumatol 1995; 14: 481-484.
55.
Adler S, Lodermeyer S, Gaa J, Heemann U. Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology (Oxford) 2008; 47: 1535-1538.
56.
Binder M, Uhl M, Wiech T, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 2012; 71: 311-312.
57.
Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 2004; 116: 194-197.
58.
Brandt AS, Kamper L, Kukuk S, Haage P, Roth S. Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol Int 2014; 93: 320-325.
59.
Maritati F, Corradi D, Versari A, et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis 2012; 71: 1262-1264.
60.
Catanoso MG, Spaggiari L, Magnani L, et al. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 2012; 30: 776-778.
61.
Vaglio A, Catanoso MG, Spaggiari L, et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum 2013; 65: 2469-2475.
62.
Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the Treatment of IgG4-Related Disease. Medicine (Baltimore) 2012; 91: 57-66.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.